Back to Search
Start Over
Evommune Initiates Phase 2 Trial of EVO756, an Oral MRGPRX2 Antagonist, in Chronic Inducible Urticaria.
- Source :
- Pharma Business Week; 9/16/2024, p701-701, 1p
- Publication Year :
- 2024
Details
- Language :
- English
- ISSN :
- 15436675
- Database :
- Complementary Index
- Journal :
- Pharma Business Week
- Publication Type :
- Periodical
- Accession number :
- 179618703